CardioExcyte 96 – Combined contractility, electrophysiology and cell viability
The CardioExcyte 96 is a hybrid system recording both contractility and electrophysiology of intact cardiomyocyte networks. In addition, the base impedance is continuously and automatically monitored as a measure of acute and chronic cell activity. No subtleties of cytotoxic responses are missed, this includes non-contractile cell types such as hepatocyte-like cells or cancer cells as well as contractile cardiac cells. Impedance and extracellular field potential measurements are performed at high resolution, are non-invasive and label-free. The CardioExcyte 96 is a fully automated device, recording from 96 wells at a time. The benefits the CardioExcyte 96 offers include:
- Impedance & extracellular field potentials from the same well
- 96 recording wells in parallel
- Non-invasive & label-free measurements
- High resolution
- Electrical and optical pacing options
- Acute and chronic assessment of cell activity and toxicity
- Validated system for CiPA
With embedded electronics and a sophisticated sensor technology integrated in the well-plate based consumables, the CardioExcyte 96 is a turn-key system for efficient impedance and extracellular field potential measurements. The CardioExcyte 96 Incubation System is an optional add-on which makes the system independent of an incubator. The system with add-on is placed on the bench top with maintained control over temperature, gas mix and humidity.
Efficiency and ease-of-use are facilitated by an outstanding software package for data handling and export - an essential part of the CardioExcyte 96 system. The system has been validated with stem cell-derived cardiomyocytes from all major stem cell providers, as monolayers or beating 3D-clusters, as well as with cell lines (hepatocyte-like cells, cancer cells etc.) for cytotoxicity studies.
For detailed information:
Add-Ons and Features
CardioExcyte 96 Platform
The CardioExcyte 96 package contains an Integra Viaflo Assist that provides automated multichannel pipetting for reproducible 96 well plate handling of cells and compounds.
CardioExcyte 96 Incubation System (Add-On)
The CardioExcyte 96 can either be placed in a humidified incubator, or outside an incubator when equipped with the CardioExcyte 96 Incubation System. The CardioExcyte 96 Incubation System controls temperature, gas mix and humidity.
CardioExcyte 96 SOL (Add-On)
Optical stimulation and investigation of impedance and extracellular field potentials in parallel:
The stimulating optical lid, CardioExcyte 96 SOL, uses LEDs for spatially uniform stimulation of cells transfected with light-gated ion channels such as Channelrhodopsin2 (ChR2). After transfection of iPS cardiomyocytes with ChR2 the cells can be stimulated by blue light. Each light impulse induces a depolarization of the cells and thus an action potential is triggered. The advantages of optical stimulation over electrical stimulation include the highly precise timing, all cells of the beating network are stimulated exactly at the time of the light stimulus. In contrast, electrical stimulation propagates from the electrode across the well and thus cells are stimulated progressively. A mean beat calculation of precisely timed beats enables in-depth compound analysis and concentration response dependencies to be obtained. This is one of the key software capabilities of the CardioExcyte Control/ DataControl software package that is provided with each CardioExcyte 96 system.
CardioExcyte 96 Software package
The CardioExcyte Control software supports online analysis of beating parameters. The unique Mean Beat Function automatically visualizes the average of beat traces from one well, enveloped by the standard deviation, indicating the consistency of the beat pattern within the recording well, i.e. if the cellular network is synchronously beating or not. The control software is intuitive and easy-to-use, at the same time very powerful in terms of experimental setup and online visualization of the recorded data.
The DataControl 96 software package is an independent software package to load and analyze data recorded on the CardioExcyte 96.The analysis template can be saved and reloaded. Customized export formats of analysis results are integrated.
The Online Analysis Post Processor (OAPP) is a software tool enabling quick visualization of well-to-well statistics and concentration dependent effects. Parameters and traces can be normalized to control values or time points. Export of graphics is straightforward making OAPP a highly versatile tool for the analysis routine.
Statement about the DataControl 96 Package
The NSP-96 chip is a proprietary innovative product by Nanion Technologies, developed for the CardioExcyte 96. It is produced and quality-assured partly by an external partner and partly in-house at Nanion headquarters and shipped from Munich to our international customers. Different types of NSP-96 chips are available for different experiments.
Description and Material
- Standard 96-well plate format
- Working volume: 25-340 µl (surface 34mm2)
- Planar, bipolar circular gold electrodes
- Supports recordings from 2D and 3D structures
- Hybrid sensor design for both EFP and impedance recordings
Available chip types
- "NSP-96, CardioExcyte 96 Sensor Plates - Stim": Type standard with extra stimulation electrode (Order # 201003)
- "NSP-96 CardioExcyte96 Sensor Plates 0.6 mm": Type standard, 0.6 mm recording electrode (Order # 201002)
- "NSP-96 CardioExcyte96 Sensor Plates 2.0 mm": Type standard, 2.0 mm recording electrode (Order # 201001)
Other types are available upon request!
CardioExcyte 96 & CiPA
CiPA - Comprehensive In Vitro Proarrhythmia Assay
Nanion, a committee member of the Health and Environmental Science Institute (HESI) cardiac safety and HTS teams, has a long-standing interest and extensive experience in automated patch clamp screening of cardiac ion channels. Furthermore, label-free impedance and extracellular field potential recordings of stem cell-derived cardiomyocytes (SC-CMs) is also available in our portfolio. Our instruments are used for safety screening by major pharmaceutical companies and CROs worldwide and we are happy to assist you in setting up your CiPA assays. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative aims to replace the preclinical hERG current assay required under the ICH S7B safety pharmacology guidelines and clinical TQT study, which provides a surrogate marker of Proarrhythmia, with more translationally relevant assessments of proarrhythmic risk (Sager et al., 2014). CiPA will achieve this by evaluating proarrhythmic risk of evolving drug candidates based on an understanding of the electrophysiologic mechanisms responsible for proarrhythmia linked to Torsades de pointes (TdP) and QT prolongation. The three components of CiPA include voltage clamp assessment of human ion channels, in silico reconstruction of electrophysiologic activity and confirmation using in vitro assays on human SC-CMs.
Recommended Readings on the Role of the CardioExcyte 96 in the CiPA study
Testimonials & Case Studies
Data and Applications
Webinars and Movies
Movies: Tutorials and Oral Presentations